DCT

1:25-cv-01330

Novartis Pharma Corp v. Apotex Inc

Log In
Key Events
Amended Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: 1:25-cv-01330, D. Del., 06/30/2026
  • Venue Allegations: Venue is alleged to be proper as to Apotex Corp. because it is a Delaware corporation. Venue is alleged as to Apotex Inc. because it is a Canadian corporation subject to personal jurisdiction in the district.
  • Core Dispute: Plaintiff alleges that Defendants' submission of an Abbreviated New Drug Application (ANDA) seeking to market a generic version of the cancer drug Mekinist® constitutes an act of infringement of five patents covering pharmaceutical compositions and methods of use.
  • Technical Context: The technology relates to pharmaceutical formulations of trametinib, a MEK inhibitor used to treat certain types of melanoma, designed to improve the drug's stability and bioavailability.
  • Key Procedural History: This Hatch-Waxman action was triggered by notice letters from Apotex to Novartis, informing Novartis of Apotex's ANDA filing (No. 220471) containing Paragraph IV certifications against the patents-in-suit. This First Amended Complaint follows an original complaint to which Defendants have already answered, and Defendants do not contest personal jurisdiction in Delaware for the limited purposes of this action.

Case Timeline

Date Event
2009-10-16 '781 Patent Priority Date
2010-12-20 '304, '706, '941, '021 Patents Priority Date
2013-11-12 U.S. Patent No. 8,580,304 Issued
2014-04-22 U.S. Patent No. 8,703,781 Issued
2015-10-13 U.S. Patent No. 9,155,706 Issued
2016-03-01 U.S. Patent No. 9,271,941 Issued
2016-07-26 U.S. Patent No. 9,399,021 Issued
2025-09-17 Apotex sends First Notice Letter to Novartis
2026-05-20 Apotex sends Second Notice Letter to Novartis
2026-06-30 First Amended Complaint Filed

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 8,580,304 - "Pharmaceutical Composition," issued November 12, 2013

The Invention Explained

  • Problem Addressed: The patent background describes challenges in creating a stable, solid oral dosage form for the anti-cancer drug trametinib (referred to as Compound B) '304 Patent, col. 2:35-44 The drug's solvate form (Compound A) can revert to a much less soluble, desolvated form when exposed to moisture, negatively impacting its pharmacodynamics, and it also suffers from photo-instability '304 Patent, col. 3:58-4:6 '304 Patent, col. 6:55-59
  • The Patented Solution: The invention is a pharmaceutical tablet formulated with the trametinib dimethyl sulfoxide solvate (Compound A) using specific techniques to ensure stability and consistent drug delivery '304 Patent, abstract The solution involves formulating the tablet with excipients that are "substantially free of water" and controlling the manufacturing process to ensure the amount of the undesirable unsolvated drug form remains below a certain threshold (e.g., 20%) '304 Patent, col. 2:45-48 '304 Patent, col. 6:59-64
  • Technical Importance: This formulation provided a path to a commercially viable oral tablet for a potent MEK inhibitor, addressing stability and bioavailability issues critical for consistent and safe dosing in cancer therapy '304 Patent, col. 2:30-34

Key Claims at a Glance

  • The complaint asserts independent claim 1 and dependent claim 8 Compl. ¶43
  • The essential elements of independent claim 1 are:
    • A pharmaceutical tablet comprising:
    • an amount of a drug, which is N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide dimethyl sulfoxide solvate;
    • the tablet contains from about 25% to about 89% by weight of one or more excipients, where the excipients are substantially free of water; and
    • the amount of unsolvated drug does not exceed about 20%.
  • The complaint reserves the right to assert additional claims Compl. ¶50

U.S. Patent No. 9,155,706 - "Pharmaceutical Composition," issued October 13, 2015

The Invention Explained

  • Problem Addressed: The patent, part of the same family as the '304 patent, addresses the "poor exposure and absorption upon in vivo administration" of trametinib, which is a consequence of its low solubility '706 Patent, col. 5:4-5
  • The Patented Solution: The invention claims a pharmaceutical tablet of the trametinib solvate where the drug particles are processed to be a specific small size ("micronized") '706 Patent, abstract As illustrated in pre-clinical studies, reducing the particle size significantly improves drug exposure (AUC) compared to unmicronized drug, overcoming the bioavailability problem '706 Patent, FIG. 1 The patent specifies that at least 50% of the drug particles should have a particle size of 30 microns or less '706 Patent, col. 5:7-14
  • Technical Importance: Micronization provided a crucial formulation strategy to ensure that a sufficient and consistent amount of the low-solubility oral anti-cancer drug would be absorbed by the body, a key factor for therapeutic efficacy '706 Patent, col. 35:40-44

Key Claims at a Glance

  • The complaint asserts independent claim 1 and dependent claims 8 and 16 Compl. ¶68
  • The essential elements of independent claim 1 are:
    • A pharmaceutical tablet comprising:
    • an amount of a drug, which is N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide dimethyl sulfoxide solvate;
    • wherein, at least 50% of the drug particles have a particle size of 30 micron or less.
  • The complaint reserves the right to assert additional claims Compl. ¶74

U.S. Patent No. 9,271,941 - "Pharmaceutical Composition," issued March 1, 2016

  • Technology Synopsis: The '941 patent, which is in the same family as the '304 and '706 patents, claims pharmaceutical tablets of trametinib dimethyl sulfoxide solvate. The invention addresses the same stability and bioavailability problems by requiring that the tablet excipients be "substantially free of water" and/or that the drug particles have a size of 30 microns or less Compl. ¶87
  • Asserted Claims: Independent claim 1 and dependent claim 8 Compl. ¶91
  • Accused Features: Apotex's ANDA Product is alleged to be a tablet formulation of trametinib dimethyl sulfoxide solvate that contains excipients substantially free of water and has a drug particle size of 30 microns or less Compl. ¶¶92-94

U.S. Patent No. 9,399,021 - "Pharmaceutical Composition," issued July 26, 2016

  • Technology Synopsis: The '021 patent, also in the same family, claims pharmaceutical tablets of trametinib dimethyl sulfoxide solvate designed to solve the bioavailability problem. The invention requires that the drug particles in the tablet are "micronized" and/or have a particle size of 30 microns or less Compl. ¶110
  • Asserted Claims: Independent claim 1 and dependent claims 8 and 17 Compl. ¶115
  • Accused Features: Apotex's ANDA Product is alleged to be a tablet containing micronized trametinib dimethyl sulfoxide solvate particles, at least 50% of which have a particle size of 30 microns or less Compl. ¶¶117-118

U.S. Patent No. 8,703,781 - "Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors," issued April 22, 2014

  • Technology Synopsis: The '781 patent claims combinations of trametinib (a MEK inhibitor) with dabrafenib (a B-RAF inhibitor) as well as methods of treating melanoma by administering the combination. The invention is based on the therapeutic synergy of jointly inhibiting both the MEK and B-Raf pathways in cancer treatment Compl. ¶134 '781 Patent, abstract
  • Asserted Claims: Independent claim 1 Compl. ¶139
  • Accused Features: The complaint alleges that Apotex intends to market its trametinib ANDA product for use in combination with its generic dabrafenib product to treat melanoma. This alleged intent to encourage combined use is the basis for the infringement allegation against this method-of-use patent Compl. ¶¶141-148

III. The Accused Instrumentality

Product Identification

  • Apotex's proposed generic version of Mekinist® (trametinib dimethyl sulfoxide) tablets in 0.5 mg and 2 mg strengths, as described in ANDA No. 220471 Compl. ¶2 Compl. ¶3

Functionality and Market Context

  • The complaint alleges, on information and belief, that the accused product is a pharmaceutical tablet containing the solvate form of trametinib Compl. ¶44 The formulation is alleged to possess specific physical and chemical properties, including the use of excipients that are "substantially free of water" Compl. ¶45, a limit on the amount of unsolvated drug Compl. ¶46, and a small, "micronized" drug particle size Compl. ¶47 Compl. ¶71 The accused product is intended as a lower-cost generic alternative to Novartis's branded Mekinist® product for treating certain types of melanoma Compl. ¶¶33-34

No probative visual evidence provided in complaint.

IV. Analysis of Infringement Allegations

The infringement allegations for the formulation patents are made on "information and belief," as the specific details of Apotex's ANDA are not public Compl. ¶35 The analysis will depend on the actual characteristics of the ANDA product as revealed during litigation.

U.S. Patent No. 8,580,304 Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
a) an amount of a drug, which is N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide dimethyl sulfoxide solvate... The ANDA Product is alleged to be a pharmaceutical tablet that contains trametinib dimethyl sulfoxide solvate. ¶44 col. 41:31-42
b) the tablet contains from about 25% to about 89% by weight of one or more excipients, where the excipients are substantially free of water; The ANDA Product is alleged to contain from about 25% to about 89% by weight of one or more excipients that are substantially free of water. ¶45 col. 2:45-48
and c) the amount of unsolvated drug does not exceed about 20%. The amount of unsolvated drug in the ANDA Product is alleged not to exceed about 20%. ¶46 col. 6:59-64

U.S. Patent No. 9,155,706 Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
a) an amount of a drug, which is N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide dimethyl sulfoxide solvate... The ANDA Product is alleged to be a pharmaceutical tablet that contains trametinib dimethyl sulfoxide solvate. ¶69 col. 1:11-20
wherein, b) at least 50% of the drug particles have a particle size of 30 micron or less. At least 50% of the drug particles in the ANDA Product are alleged to have a particle size of 30 microns or less. ¶70 col. 5:7-14

Identified Points of Contention

  • Factual Questions: For the '304, '706, '941, and '021 patents, the central dispute will be factual. The case will turn on whether Apotex's confidential ANDA formulation, once produced in discovery, actually has the claimed properties related to water content, percentage of unsolvated drug, and particle size distribution. The complaint's allegations are necessarily based on "information and belief" pending this discovery Compl. ¶35 Compl. ¶44
  • Scope Questions: The definition of "substantially free of water" in the '304 and '941 patents is a potential area for claim construction disputes. The parties may contest the precise level of moisture allowable in the excipients for the ANDA product to fall within the claim scope. Similarly, the term "micronized" in the '706 and '021 patents may raise questions about whether it implies a specific process or merely a resulting particle size.
  • Indirect Infringement Question: For the '781 patent, the dispute centers on indirect infringement. The question for the court will be whether Novartis can prove that Apotex's proposed labeling and marketing activities for its trametinib and dabrafenib products demonstrate a specific intent to encourage medical professionals to prescribe them together in an infringing manner (Compl. ¶¶142-148).

V. Key Claim Terms for Construction

  • The Term: "substantially free of water" (from '304 Patent, claim 1)

    • Context and Importance: This term is qualitative and central to the infringement analysis of the '304 and '941 patents. Its construction will determine the threshold for how much moisture can be present in the accused product's excipients. Practitioners may focus on this term because the ANDA product will likely contain some amount of water, making the definition of "substantially" dispositive.
    • Intrinsic Evidence for Interpretation:
      • Evidence for a Broader Interpretation: The specification states that the term "includes anhydrous versions of non-anhydrous excipients," which may support an argument that the term does not require absolute dryness and allows for standard pharmaceutical-grade excipients that are not specially treated to remove all water '304 Patent, col. 2:45-48
      • Evidence for a Narrower Interpretation: The patent repeatedly emphasizes that the invention's purpose is to avoid desolvation caused by moisture '304 Patent, col. 3:58-4:3 A party could argue this context requires a very low level of water to achieve the patented benefit. The specification also notes that an excipient could contain "about 5% by weight or less" of water, which may be cited as an explicit upper boundary '304 Patent, col. 22:64-67

  • The Term: "micronized" (from '706 Patent, claim 8 and '021 Patent, claim 1)

    • Context and Importance: This term defines a key physical characteristic of the drug substance aimed at improving bioavailability. The infringement analysis for the '706 and '021 patents hinges on whether Apotex's drug particles meet this definition.
    • Intrinsic Evidence for Interpretation:
      • Evidence for a Broader Interpretation: The specification provides a process-oriented definition, stating that "micronized" means the drug particles are processed "to significantly reduce particle size over those produced naturally during chemical synthesis" '706 Patent, col. 35:49-53 This could support a reading that any process achieving this result qualifies.
      • Evidence for a Narrower Interpretation: The specification also provides a specific, exemplary particle size distribution: "X50: 1.0-4.2 µm" and "X90: NMT 10.6 µm" '706 Patent, col. 36:10-12 A party may argue that to be considered "micronized" in the context of this patent, the particles must fall within or near these disclosed ranges, not just be smaller than the starting material.

VI. Other Allegations

Indirect Infringement

  • The complaint alleges that Apotex will actively induce infringement of all patents-in-suit. For the formulation patents, this is based on the proposed product labeling, which allegedly will instruct or encourage use of the ANDA product in an infringing manner Compl. ¶52 Compl. ¶76 Compl. ¶99 Compl. ¶123 For the '781 method patent, inducement is the central allegation, based on Apotex's alleged business strategy to market its trametinib and dabrafenib products for combined use in treating melanoma, supported by activities including "product catalogs, formulary submissions, pricing materials," and other promotional materials Compl. ¶¶143-148

Willful Infringement

  • The complaint does not explicitly plead willful infringement. However, it alleges that Apotex had knowledge of the patents-in-suit via the notice letters and "knowingly and deliberately challenged Novartis's patent rights" Compl. ¶16 Compl. ¶24 Compl. ¶52 The prayer for relief seeks a declaration of an "exceptional case" and an award of attorneys' fees, which is the remedy for willful infringement or other litigation misconduct Compl. p. 28, prayer "e" These allegations preserve the option to pursue enhanced damages based on post-suit knowledge of infringement.

VII. Analyst's Conclusion: Key Questions for the Case

  1. A central evidentiary question for the four formulation patents ('304, '706, '941, '021) will be one of factual correspondence: does the chemical composition and physical structure of Apotex's proposed generic product, as detailed in its confidential ANDA, actually fall within the specific numerical ranges for excipient water content, unsolvated drug percentage, and particle size distribution claimed by the patents?

  2. A primary legal question for the combination patent ('781) will be one of induced infringement: will the collective evidence of Apotex's proposed product labels, marketing materials, and business strategy be sufficient to prove Apotex possessed the specific intent to encourage physicians to co-prescribe its separate trametinib and dabrafenib products in a manner that directly infringes Novartis's patented method of treatment?

  3. The case may also turn on a key issue of claim construction: how will the court define the term "substantially free of water"? A narrow construction requiring near-anhydrous conditions could place the accused product outside the claims' scope, whereas a broader construction allowing for typical levels of moisture in standard excipients may support a finding of infringement.

Loading Amended Complaint